Trial Profile
A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Subjects to Determine the Effect of an Inhibitor of Cytochrome P450 3A on Exposure to Relacorilant and Its Main Metabolites
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Relacorilant (Primary) ; Itraconazole
- Indications Cushing syndrome; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
- 23 Mar 2020 Status changed from recruiting to completed.
- 07 Jun 2019 Planned number of patients changed from 48 to 52.
- 07 Jun 2019 Planned End Date changed from 31 Jul 2019 to 31 Aug 2019.